Current Infraprojects IPO...
20 Aug, 2025
Asston Pharmaceuticals IPO
Asston Pharmaceuticals is coming with its IPO, which is one of the fastest-growing pharmaceutical firms that specializes in selling medical products across the world. The new 22.41 lakh shares being issued by Asston Pharmaceuticals IPO are priced between ₹115 and ₹123 per share, with a face value of ₹10 per share. The opening date of the IPO is going to be 7th July 2025, while the closing date on 9th July 2025. The IPO offering size is 1000 shares in one lot and for a retail individual investor, a minimum investment of 2000 shares is needed.
Company Background
Asston Pharmaceuticals Limited was founded in 2019 with the goal of distributing a variety of medical supplies throughout the world. Its offerings include tablets, capsules, sachets and syrups across various therapeutic areas like antibiotics, antifungals and vitamins. The company operates through both direct sales and contract manufacturing or a loan license agreement under a principal-to-principal model. Because of the company's Central and State FDA certifications, NQA accreditation, and adherence to QMS standards, high-quality production is guaranteed.
Operations and Product Range
Facility and Production
Asston Pharmaceuticals IPO has manufacturing facilities with a capacity to produce 8–9 crore tablets per month, 30–40 lakh sachets monthly and approximately 37,500 liters of syrups each month. The company’s production adheres to high-quality standards as it is certified by the Central and State FDA, accredited by NQA and compliant with Quality Management System (QMS) protocols. This ensures consistent manufacturing of pharmaceutical products including tablets, capsules, syrups and sachets.
Brand and Market Presence
The company has its brand name “Asston” under which it markets its products and also manufactures products with contract manufacturing or license agreements for other marketers as well. The product line of the company includes important therapeutic categories such as vitamins, antibiotics, antifungals and more. Asston Pharmaceuticals IPO has created a significant position in both domestic and international markets by exporting its products in the Asian and African nations.
Revenue Channels
Asston Pharmaceuticals IPO generates revenue primarily through:
- Contract Manufacturing (Loan License / B2B): For major revenue, the company mainly produces pharmaceutical products for third-party marketers under loan license agreements.
- Branded Product Sales: Another major chunk of revenue comes from selling formulation drugs under the company's brand name “Asston”, including tablets, syrups and sachets.
- Export Sales: Asston also exports its pharmaceutical and nutraceutical products to the African and Asian region, which also help in the company’s revenue.
- OTC & Nutraceutical Products: Offering over-the-counter formulations such as vitamin syrups and mineral supplements through retail and pharmacy channels.
Management & Shareholding
Promoters & Shareholding
Asston Pharmaceuticals IPO is promoted by Dr. Ashish Narayan Sakalkar, Saili Jayaram More, and Sachin Chandrakant Badakh. Before the IPO, promoters held 68.76% equity, which will reduce to 50.66% post-issue.
Board Members
The board includes Managing Director Dr. Ashish Sakalkar and Director/CEO Saili More, both appointed in April 2019. In June 2024, Sachin Badakh became a Non-Executive Director. Independent directors Rishabh Kumar Jain and Vijaya Shahapurkar also serve on the board.
WHAT IS GMP?
GMP (Grey Market Premium) is the difference between the IPO price and the grey market price. It is the premium amount paid for the traded IPO shares. It plays an important role in IPOs as it reflects how the IPO would react on the listing day.
A grey market is a place where shares/stocks are traded before being listed officially on the stock exchange.
Asston Pharmaceuticals IPO
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| - | - | - | - |
**The GMP prices displayed here are solely for informational purposes related to the grey market news. India IPO does not engage in or facilitate grey market trading, nor are these rates (sub2) indicative of any trading activity. We also do not recommend or endorse participation in the grey market.**
Asston Pharmaceuticals IPO Details
| Detail | Description |
|---|---|
| IPO Date | July 9, 2025 to July 11, 2025 |
| Listing Date | - |
| Face Value | ₹10 per share |
| Issue Price Band | ₹115 to ₹123 per share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 22,41,000 shares (aggregating up to ₹27.56 Cr) |
| Reserved for Market Maker | 1,13,000 shares (aggregating up to ₹0.0015 Cr) |
| Net Offered to Public | 21,28,000 shares (aggregating up to ₹26.17 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 62,71,360 shares |
| Share Holding Post Issue | 85,12,360 shares |
Asston Pharmaceuticals IPO Timeline
| Detail | Description |
|---|---|
| IPO Open Date | Wed, Jul 9, 2025 |
| IPO Close Date | Fri, Jul 11, 2025 |
| Tentative Allotment | Mon, Jul 14, 2025 |
| Initiation of Refunds | Tue, Jul 15, 2025 |
| Credit of Shares to Demat | Tue, Jul 15, 2025 |
| Tentative Listing Date | Wed, Jul 16, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on July 11, 2025 |
Asston Pharmaceuticals IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2000 | ₹2,46,000 |
| Individual investors (Retail) (Max) | 2 | 2000 | ₹2,46,000 |
| S-HNI (Min) | 3 | 3000 | ₹3,69,000 |
| S-HNI (Max) | 8 | 8000 | ₹9,84,000 |
| B-HNI (Min) | 9 | 9000 | ₹11,07,000 |
Asston Pharmaceuticals IPO Promoter Holding
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| 68.76% | 50.66% |
Competitive Strength:
- ● Broad Product Portfolio: Numerous pharmaceutical and nutraceutical products.
- ● Export Focus: Strong presence in African and Asian markets.
- ● Experienced Leadership: Promoters with 25+ years of industry experience.
- ● Quality Certifications: FDA, FSSAI, WHO GMP and NABL accreditations.
- ● Flexible Manufacturing: Mix of in-house and contract manufacturing.
Asston Pharmaceuticals IPO Financial Information
| Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Total Borrowing | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 May 2025 | 31.83 | 6.21 | 1.32 | 12.04 | 7.83 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2025 | 28 | 26 | 4 | 11 | 7.26 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2024 | 20.26 | 15.84 | 1.36 | 6.39 | 6.82 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2023 | 13.69 | 7.19 | 1.06 | 1.99 | 5.25 | |||||||||||||||||||||||||||||||||||
| Amount in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||
Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 50.56% |
| ROCE | 51.25% |
| Debt/Equity | 0.68 |
| RoNW | 40.36% |
| PAT Margin | 17.27% |
| EBITDA Margin | 24.60% |
| Price to Book Value | 12.07 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 6.9 | 9 |
| P/E (x) | 17.83 | 13 |
The objective of Asston Pharmaceuticals IPO
The objective of the Asston Pharmaceuticals IPO is to:
- Finance the capital investment needed to buy new equipment for the production facility.
- Meet the company's increased working capital needs.
- Repay or prepay certain outstanding borrowings.
- General corporate purposes
Conclusion
Asston Pharmaceuticals IPO offers investors exposure to a fast-growing, export-oriented pharmaceutical company with a diverse product range and strong financial performance. The company’s strengths include experienced leadership, quality certifications and a flexible manufacturing model. However, risks such as reliance on a few export markets, regulatory challenges and a short operating history remain. The IPO aims to fund machinery purchases, working capital needs, debt repayment and general corporate purposes, supporting further growth and operational expansion.
RHP:
DRHP:
Read more :
Frequently asked Questions (FAQs )
-
1. What are the IPO dates?
The initial public offering (IPO) day is July 9, 2025 and it ends on July 11, 2025.
-
2. What is the IPO pricing range?
The pricing range for each equity share is ₹115 to ₹123.
-
3. What is the minimum investment required?
An individual investor must invest ₹2,46,000 and the minimum lot size is 2,000 shares.
-
4. Where will the shares be listed?
The BSE SME platform is where the shares are expected to be listed.
-
5. When is the allotment and listing date?
The dates of allocation and listing are July 14, 2025 and July 16, 2025, respectively.
